as poor feeding and diarrhea, autonomic dysregulation, and respiratory abnormalities. 2 The national incidence of NAS has increased 5-fold between 2000 and 2012, now accounting for 3% of all neonatal intensive care unit (NICU) admissions and contributing to significant health expenditures. [3] [4] [5] Opioid use disorders in pregnancy are associated with an increased risk for premature delivery. Of all pregnant women on methadone maintenance therapy, 20% to 40% deliver prematurely compared with 11% in the general population. [6] [7] [8] The ideal way to evaluate and treat premature infants with NAS is unknown, with available symptom-based scoring systems designed for use in full-term infants. 6 , 9-16 Few studies have examined NAS manifestations in preterm infants. Preterm infants are reported to have a lower risk of developing NAS with lower peak NAS scores than term infants. 13 , 14 Preterm infants have also been shown to require lower doses of replacement opioid medications and have a shorter duration of opioid therapy than infants born at term. 10 It is hypothesized that an underdeveloped central nervous system, decreased hepatic clearance of methadone, and a lower 330 Allocco et al cumulative in utero opioid exposure may decrease manifestations of NAS. 10 , 14 Several symptom-based scoring tools have been developed to quantify the presence and severity of symptoms of opioid withdrawal in full-term neonates. 11 , 12 , 16 , 17 The Neonatal Abstinence Scoring System (NASS), more commonly referred to as the Finnegan scale, requires frequent monitoring of the infant and recording of the presence and severity of 31 items. 11 The NASS has become the most commonly used tool to guide pharmacologic treatment. Using this scale as part of a strict assessment and pharmacologic weaning protocol has been shown to result in a shorter duration of treatment and shorter length of hospital stay. 18 The NASS was validated for use with infants delivered at term but has not been evaluated in preterm infants. 11 An intraobserver reliability program exists for the NASS and is widely used as best practice for term infants with NAS to ensure consistency in assessments. The other available scoring tools such as the Lipsitz scale, Neonatal Narcotic Withdrawal Index, Neonatal Withdrawal Inventory, and the MOTHER study modified Finnegan scale were also designed for use in full-term infants but are less frequently used in clinical practice. 11, 12, 16, 17, 19 It is unclear how prematurity and its associated morbidities affect the ability of the available NAS scoring tools to accurately capture NAS symptoms in the preterm population. 20 As preterm delivery is increased in the presence of maternal opioid use disorders, it is important to accurately identify and appropriately treat NAS in these infants. 6 , 13 The objective of this study was to compare the NAS symptom profile in preterm methadone-exposed infants versus matched term controls as a first step toward developing a custom NAS scoring tool for preterm infants that will help guide optimal pharmacologic treatment of this high-risk population.
METHODS

Study Design
This was a retrospective cohort study of pregnant women with opioid use disorders and their infants delivered at Boston Medical Center (BMC), a tertiary care center with a level III NICU, from June 2006 to December 2010. BMC cares for the largest population of infants with NAS in Massachusetts and one of the largest in the country with 150 opioid-exposed newborns annually. BMC has a specialty prenatal clinic Project RESPECT, which is an established national leader in the care of pregnant women with substance use disorders. 21 The entire database included 332 infants from 326 pregnancies that were born to 310 women administered methadone or buprenorphine maintenance therapy. This study was approved by the Boston University Medical Center Institutional Review Board. There were 45 methadone-exposed preterm ( < 37 weeks' gestational age) infants during the study period and 6 preterm buprenorphine-exposed infants in the database. Given the small number of preterm buprenorphine-exposed infants, only the methadone-exposed infants were examined in this study. From the remaining 200 full-term methadoneexposed infants, 49 were randomly selected as matched controls. Controls were matched on the basis of month and year of birth and then compared for baseline characteristics.
Data were obtained from electronic medical records and included maternal age, prenatal drug exposures, details of methadone and buprenorphine treatment during the pregnancy, concomitant psychiatric medication use, gestational age at delivery, mode of delivery, infant birth weight, infant comorbidities and diagnoses, as well as neonatal abstinence scores using a modified Finnegan scale (see Appendix 1), amount and duration of NAS pharmacologic treatment, and length of infant hospital stay. The frequency of scoring for each Finnegan scale item was collected for all infants over the duration of their hospitalization. Infants were scored every 3 to 4 hours, with routine newborn cares starting within 6 hours of birth and continuing either until 5 to 7 days of life (for infants who do not require pharmacotherapy) or 24 to 48 hours after discontinuation of medication. Pharmacologic treatment with first-line therapy was initiated if the infant had 3 consecutive modified Finnegan scale scores of 8 or more or 2 consecutive scores of 12 or more. Firstline therapy for NAS varied during the study period, with phenobarbital used until 2006 and then diluted tincture of opium (DTO) of 0.4 mg of morphine/mL from 2006 to 2009, and infants delivered mid-January 2009 through December 2010 had first-line treatment with neonatal morphine solution. In our statistical analyses, the amount of morphine in the total DTO dose administered was determined for DTO-treated neonates. Morphine dosing was based on both severity of scores and neonatal birth weight. Adjunctive therapy with phenobarbital or clonidine was added for infants who continued to have scores of 8 or more despite maximum dosing of DTO or morphine. Infants were weaned off DTO, morphine, and/or clonidine as inpatients and monitored for 24 to 48 hours prior to discharge. Phenobarbital was weaned in the outpatient setting.
What This Study Adds
• This study highlights the differences in symptom profile between preterm and term opioid-exposed infants, necessitating development of a preterm neonatal abstinence syndrome scoring tool.
Statistical Methods
Maternal and infant demographics factors and infant NAS outcomes were compared using independent-samples t tests and χ 2 test as appropriate in the preterm versus term groups. Then, the frequency of scoring for each Finnegan scale item was compared using the χ 2 test in the preterm versus term infants. Median, interquartile range (IQR), risk difference, risk ratio, and corresponding 95% confidence intervals (CIs) were calculated. A multivariable model was then created adjusting for covariates associated with both preterm birth and NAS outcomes including prenatal use of psychiatric medications. Assuming an average of 20 days of 6 Finnegan scale scores per day per infant, we will have more than 90% power to detect a 5% difference in scoring frequency between the preterm and term groups. Among infants with diagnoses of respiratory disorders (meconium aspiration, respiratory distress syndrome, transient tachypnea of the newborn), feeding difficulties (immature feeding requiring feeding tube), necrotizing enterocolitis, neurologic disorders (intraventricular hemorrhage, hypoxic ischemic encephalopathy), sepsis, and temperature instability requiring isolette, we compared the proportion of scoring for related items on the Finnegan scale. All analyses were performed using SAS (version 9.4).
RESULTS
The demographics of our mother-infant pairs are shown in Tables 1 and 2 . The median gestational age was 39 weeks (IQR = 38-40) in the term group (n = 49) and 35 weeks (IQR = 33-36) in the preterm group (n = 45). More mothers in the preterm group were taking prescribed psychiatric medications ( Table 1 ). The median birth weight was lower, and incidence of respiratory diagnoses, feeding immaturity, and temperature instability was higher in the preterm group. NAS outcomes including need for pharmacologic treatment (98% in the term vs 91% in the preterm), need for adjunctive medication therapy, and length of hospitalization did not differ significantly between the 2 groups ( Table 2 ) . A total of 6544 scores for the preterm and 7422 scores for the term infants were documented, with a mean of 149 scores per infant during the hospitalization ( Table 3 ). Preterm infants differed significantly in the frequency of scoring for 14 of the 19 items on the Finnegan scoring tool ( Figure 1 ). Specifically, preterm infants scored less frequently for sleep disturbance, tremors, restlessness, increased muscle tone, excoriations, sweating, fever, nasal stuffiness, sneezing, excessive sucking, and loose stools than full-term controls ( P < .05). Preterm infants scored more frequently for hyperactive moro reflex, tachypnea, and poor feeding ( P < .05). The preterm group scored for items sweating, yawning, nasal flaring, and regurgitation/vomiting less than 5% of the time ( P < .05) ( Figure 1 , Table 3 ). When adjusted for exposure to any psychiatric medication (benzodiazepines, selective serotonin reuptake inhibitors, and/or other psychiatric medications), the mean differences in scoring frequency between preterm and term groups for restlessness, fever, tachypnea, excessive sucking, regurgitation, loose stools, and excoriations were no longer statistically significant. Adjustment for psychiatric medications increased the mean differences in scoring frequency between preterm and term infants for crying, sleep, moro reflex, tremors, tone, sweating, nasal stuffiness, sneezing, and poor feeding ( P < .05).
For infants with a respiratory diagnosis, the frequency of scoring for the Finnegan scale item of respiratory distress was higher when compared with infants without a respiratory diagnosis (25.7% vs 17.5%; mean difference of 8.3% [95% CI, 5.6-10.3]; P < .05). Similarly, for infants with a diagnosis of feeding immaturity requiring nasogastric feedings, the frequency of scoring for the Finnegan scale 
FIGURE 1
Frequency of scoring for Finnegan scale items in preterm (n = 45) versus term (n = 49) infants. Scoring items with frequency of less than 5% for both preterm and term infants (seizures, yawning, nasal flaring, regurgitation) are not included. a P < .05. 
DISCUSSION
We compared preterm and term methadone-exposed infants for NAS symptoms using a modified Finnegan scale, finding significant differences in the frequency of scoring for a majority of items on the scale. Specifically, we found that premature infants scored less frequently for autonomic, respiratory, and gastrointestinal symptoms. Symptoms were influenced by coexposure to maternal psychiatric medications. The differences in NAS symptoms in preterm infants and the frequency of concurrent diagnoses that cloud assessments necessitate the development of a modified scoring tool for the preterm NAS population. Altered neurobehavior including an inability to appropriately manage stimulation and stress, including during routine newborn care such as diapering and vital signs, is normal for preterm infants, but determining whether yawning, sneezing, and mottling are due to NAS or prematurity is left to the caregivers' interpretation. 22 Preterm infants demonstrate poor self-regulation and higher stress than term infants. Tone and reflexes are decreased even among healthy preterm infants; therefore, scoring items such as hypertonia are difficult to assess in the setting of concurrent NAS. 22 Because of lack of brown fat and inability to regulate temperature, heated isolettes are frequently utilized. Depending on the probe position, temperature setting, and other ambient factors, hyperthermia can result from iatrogenic causes and can complicate NAS scoring. Nasal flaring, tachypnea, and retractions are often due to respiratory distress syndrome, a known complication of prematurity related to lack of surfactant, and its relationship to NAS is difficult to discern. Poor feeding is a frequent finding of premature infants until after 32 to 34 weeks; thus, poor feeding is not a precise scoring component of NAS among preterm infants. Furthermore, regurgitation is often the result of poor lower gastroesophageal tone, presence of a nasogastric tube, and potentially not related to NAS. 20 Of particular importance in this discussion is the immaturity of the preterm brain. Preterm infants are born during a critical period of rapid brain growth and development; this can be altered by the environment and postnatal treatments, putting infants at much higher risk for neurodevelopmental impairment than their term counterparts. 23 Infants with in utero opioid exposure are also at risk for adverse neurodevelopmental outcomes, with higher reported rates of developmental delays than in the general population. [24] [25] [26] The combination of preterm birth and in utero opioid exposure puts the infant at particularly high risk for poor neurodevelopmental outcomes.
The majority of preterm infants in our study were treated with replacement opioids for NAS. There are currently no standardized treatment guidelines for opioid-exposed preterm infants, with institutional practice varying greatly and lack of any randomized trials. Opioid withdrawal, if inadequately treated, can be painful for the preterm infant, increasing stress, which could negatively affect short-term and long-term outcomes. 27 , 28 On the contrary, treatment with medications such as morphine during this critical period of brain growth comes with a potential risk of impaired neurodevelopment. 29 , 30 There is conflicting evidence on the treatment of pain in the preterm infant, with providers needing to balance the risk of pain and stress with the risk of the medication exposure. A recent study by Zwicker et al 31 found that very preterm infants exposed to neonatal morphine had decreased cerebellar growth and worse cognitive outcomes at 18 months of age. However, other studies have found that these initial differences did not persist once children were schoolaged. 29 , 30 , 32 More definitive studies are needed before recommendations can be made.
We found an increased prevalence of psychiatric medication exposure in our preterm group. Concurrent use of psychiatric medications such as benzodiazepines and selective serotonin reuptake inhibitors have been associated with more severe NAS, with higher rates of medication treatment and longer hospitalizations. 33 , 34 This likely influenced the distribution of Finnegan scale scores, particularly neurologic symptoms, which are typically associated with these medications. 35 We therefore adjusted our results for psychiatric medication exposure; results remained significant for many of the scoring items. Maternal psychiatric illness and psychiatric medication use have been reported to be associated with preterm birth, presumably related to higher maternal stress. 36 , 37 We also hypothesize that those women who delivered preterm were more unstable in their addiction, with higher rates of illicit opioid use and perhaps higher rates of psychiatric comorbidities.
The next step in this research is to develop and validate a preterm infant scoring tool, keeping in mind which symptoms are more common and specific for opioid withdrawal in the preterm population, and addressing the issue of comorbid preterm medical diagnoses. The validation process should include intraobserver reliability between providers and should be tested in a blinded fashion between opioid-exposed and control preterm infants to establish validity. In addition, the cutoff score for initiation of pharmacologic treatment should be determined using receiver operating characteristic curves before used in clinical practice. Determination of the best pharmacologic treatment regimens for preterm
Summary of Recommendations for Practice and Research
What we know:
• Maternal opioid use in pregnancy is associated with higher rates of preterm birth.
• There is currently no neonatal abstinence syndrome (NAS) scoring tool available for the preterm population . • Symptoms associated with prematurity overlap with symptoms of opioid withdrawal, making assessments diffi cult .
What needs to be studied: • The development and validation of a preterm NAS scoring tool is needed in order to better guide pharmacologic management of these infants. • Studies evaluating the optimal pharmacologic treatment regimens for opioid-exposed preterm infants are needed .
What we can do today:
• Encourage pregnant women with opioid use disorders to seek treatment with methadone or buprenorphine maintenance therapy. • Optimization of non-pharmacologic care for all opioidexposed preterm infants, including promotion of breastfeeding and clustering of infant care. • Carefully assess preterm infants with NAS, keeping in mind concurrent prematurity diagnoses that can mimic opioid withdrawal .
infants who do require therapy also requires further research. Strengths of this study include a detailed description of preterm infant symptoms for NAS in comparison with full-term infants from a center that specializes in the care of substance-exposed newborns. This study, however, has a number of limitations. First, results are based on retrospective data collection of infant's scores, without real-time evaluation of the infants and face-to-face nursing feedback on the scoring. No standardized scoring was used to ensure intrarater reliability during the study period; however, since 2013, all nurses at our hospital have undergone a reliability training program for Finnegan scale scoring, with recertification every 2 years. This was a retrospective study that aimed to identify general differences in symptoms of preterm versus term infants as a first step in the development of a new scoring tool for preterm infants. The BMC NAS treatment algorithm also changed over the study period, and nonpharmacologic care for the NAS population was not as strongly emphasized as it is in current practice.
In conclusion, preterm and term infants have different NAS symptoms and the currently available scoring tools are difficult to use in the preterm population. A scoring tool tailored to the unique characteristics of preterm infants can more accurately, and objectively, capture the experience of preterm infants with prenatal substance exposure and allow for better tailoring of pharmacologic management. This could lead to improved outcomes for this group of high-risk infants.
